# 2025年12月12日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 抗生素使用与呼吸道病毒检测阳性社区获得性肺炎住院患者结局之间的关联

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41378862)
**期刊：** Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
**PMID：** 41378862
**DOI：** 10.1093/cid/ciaf687

### 第一部分 原文与翻译

**英文原标题：** Associations between antibiotic use and outcomes in patients hospitalized with community-acquired pneumonia and positive respiratory viral assays.

> **英文摘要：**
> BACKGROUND: Newly released community-acquired pneumonia (CAP) guidelines include a conditional recommendation to treat all hospitalized patients with positive respiratory virus assays with antibacterials. We assessed the frequency, duration, and outcomes of antibacterial prescribing in this population.
> 
> METHODS: We retrospectively identified all hospitalized patients with possible CAP and a positive respiratory virus test at five hospitals, June 2015-December 2024. We used detailed clinical data to propensity-weight patients treated with 0-2 vs 5-7 days of antibacterials and compared outcomes overall and for different viruses.
> 
> RESULTS: Among 6779 patients with possible CAP and a respiratory virus, 3269 were treated with 0-2 days and 1560 with 5-7 days of antibacterials. After propensity-weighting 2614 patients (1720 treated 0-2 days, 894 treated 5-7 days), there were no significant differences in hospital length of stay (11.7 days vs 11.1 days; OR 1.05, 95% CI 0.97-1.15), ICU admission after 48 hours (28.3% vs 28.2%; OR 1.01, 95% CI 0.86-1.18), in-hospital mortality (9.5% vs 9.8%; OR 0.97, 95% CI 0.74-1.27), or 30-day hospital-free days (16.9 days vs 17.0 days; OR 0.99, 95% CI 0.95-1.03). Results were consistent when restricted to non-SARS-CoV-2 viruses and to influenza alone, when comparing 0 vs 5-7 days of antibacterials, and when restricting to patients with ICD-10 codes for pneumonia present on admission.
> 
> CONCLUSIONS: Antibacterial use for patients with possible CAP and respiratory viruses is highly variable but outcomes are similar with 0-2 vs 5-7 days of antibacterials. This suggests antibiotics are not beneficial in most CAP patients who test positive for respiratory viruses.

> **中文摘要：**
> 背景：最新发布的社区获得性肺炎（CAP）指南包含一项有条件的建议，即对所有呼吸道病毒检测阳性的住院患者给予抗菌药物治疗。我们评估了该人群抗菌药物处方的频率、疗程及其与预后的关系。
> 
> 方法：我们回顾性识别了2015年6月至2024年12月期间，在五家医院中所有疑似CAP且呼吸道病毒检测阳性的住院患者。利用详细的临床数据，对接受0–2天与5–7天抗菌药物治疗的患者进行倾向性加权，并在总体及不同病毒类型之间比较结局。
> 
> 结果：在6779例疑似CAP且呼吸道病毒检测阳性的患者中，3269例接受了0–2天，1560例接受了5–7天的抗菌药物治疗。经过倾向性加权后，共纳入2614名患者（其中1720例接受0–2天治疗，894例接受5–7天治疗）。两组在住院时间（11.7天对11.1天，OR 1.05，95% CI 0.97–1.15）、48小时后转入ICU的比例（28.3%对28.2%，OR 1.01，95% CI 0.86–1.18）、院内死亡率（9.5%对9.8%，OR 0.97，95% CI 0.74–1.27）及30天内无住院天数（16.9天对17.0天，OR 0.99，95% CI 0.95–1.03）方面差异均无统计学意义。当分析范围限定为非SARS-CoV-2病毒或仅限于流感病毒，或比较0天与5–7天抗菌治疗，或仅限于入院时具有肺炎ICD-10编码的患者时，结果一致。
> 
> 结论：在疑似CAP且呼吸道病毒阳性的患者中，抗菌药物使用差异较大，但0–2天与5–7天疗程的临床结局相似。这表明对多数呼吸道病毒阳性的CAP患者，抗生素可能并无显著获益。

### 第二部分 AI 大师评价

本研究旨在探讨呼吸道病毒检测阳性的社区获得性肺炎住院患者中，抗菌药物使用与预后之间的关系。通过多中心回顾性分析并采用倾向性加权，比较了短疗程（0–2天）与中等疗程（5–7天）抗生素治疗的效果。结果显示，两组在住院时间、ICU转入率、死亡率及住院无天数等主要结局上无显著差异。研究揭示了当前抗菌用药存在相当大的变异性，同时提示在病毒阳性CAP患者中抗生素的获益有限，具有重要的抗生素管理与临床指南优化意义。但研究仍受限于回顾性设计及潜在混杂因素。

---

## 2. 无创通气对腹部手术后低氧性呼吸衰竭患者气管再次插管的影响：NIVAS 试验的贝叶斯事后分析

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41372778)
**期刊：** Critical care (London, England)
**PMID：** 41372778
**DOI：** 10.1186/s13054-025-05795-9

### 第一部分 原文与翻译

**英文原标题：** Effect of noninvasive ventilation on tracheal reintubation among patients with hypoxemic respiratory failure following abdominal surgery: a bayesian post-hoc analysis of the NIVAS trial.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要可用。

### 第二部分 AI 大师评价

该研究基于既有的 NIVAS 随机对照试验数据，运用贝叶斯事后分析方法，探讨无创通气在腹部手术后出现低氧性呼吸衰竭患者中的再插管风险影响。此方法可在传统统计之外提供更全面的不确定性估计，帮助评估干预效应的可信度。尽管缺少摘要，题目显示研究关注术后呼吸支持策略的优化，具有较高临床价值。其创新性在于方法学的贝叶斯分析应用，但需注意因事后分析而存在的潜在偏倚。

---

## 3. 接触防护措施可防止重症监护室中产超广谱β-内酰胺酶肠杆菌科细菌的交叉传播：一项前瞻性观察研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41372670)
**期刊：** Annals of intensive care
**PMID：** 41372670
**DOI：** 10.1186/s13613-025-01589-y

### 第一部分 原文与翻译

**英文原标题：** Contact precautions prevent cross-contamination of extended-spectrum beta-lactamase-producing Enterobacterales in an intensive care unit: a prospective observational study.

> **英文摘要：**
> BACKGROUND: The spread of multidrug-resistant microorganisms (MDROs), including extended-spectrum beta-lactamase-producing Enterobacterales (ESBL-E), has increased worldwide and constitutes a significant public health challenge. International guidelines vary in their recommendations for isolation in single rooms and contact precautions regarding carriers of MDR microorganisms to mitigate cross-contamination in the ICU. The aim of this study was to investigate whether contact precautions without single-room isolation prevent cross-contamination of ESBL-E in an intensive care unit (ICU).
> 
> METHODS: All patients admitted to a general ICU during a period of 19 months were included. The study began before the COVID-19 pandemic and continued, albeit interrupted during the first wave, through the second and third wave. Rectal swabs, swabs from drainages and intravenous catheters were sampled for the detection of ESBL-E in all patients at the time of admission. Swabs were also taken from all patients co-treated with an ESBL-E-positive patient (i.e., the index patient) at the time of discharge. All cross-contaminated patient bacterial isolates were analyzed with whole-genome sequencing and compared to the isolate from the corresponding index patient.
> 
> RESULTS: Of 1042 patients admitted to the ICU, 82 patients were index patients, either known ESBL-carriers or tested positive at admission. 365 ESBL-E-negative patients (n=365) at ICU admission were co-treated in the same room as an index patient during their ICU-stay. Post-ICU discharge, three patients from the latter group tested positive for ESBL-E. No bacterial ESBLisolates from the latter patients corresponded to those of the index patients when their bacterial genomes were identified and compared.
> 
> CONCLUSIONS: Contact precautions without single-room isolation of ESBL-E-positive patients did not result in any cross-contamination between ICU-patients in an endemic setting with a short length of stay.

> **中文摘要：**
> 背景：包括产超广谱β-内酰胺酶肠杆菌科细菌（ESBL-E）在内的多重耐药微生物（MDROs）传播在全球范围内日益增加，构成了严重的公共卫生挑战。国际指南对于单人病房隔离及针对携带耐药微生物患者的接触防护措施建议不一，其目的是减少重症监护病房（ICU）中的交叉传播。本研究旨在探讨在无单人病房隔离的情况下，仅采取接触防护措施是否能预防ICU内ESBL-E的交叉传播。
> 
> 方法：纳入19个月期间入住综合性ICU的所有患者。研究始于新冠疫情之前，第一波疫情期间虽有中断，但随后在第二、三波期间继续进行。所有患者在入院时均采集直肠拭子、引流物及静脉导管拭子，以检测是否携带ESBL-E。同时，对在ICU住院期间与ESBL-E阳性患者（即指数患者）同室治疗的所有患者，在出院时采样。所有可能出现交叉污染的病人菌株均经全基因组测序分析，并与相应指数患者的菌株进行比较。
> 
> 结果：在入院的1042例ICU患者中，有82例为指数患者，即既往已知为ESBL携带者或入院时检测为阳性。在ICU入院时ESBL-E阴性的患者中，有365例在住院期间与指数患者同室。ICU出院后，其中3例患者检测出ESBL-E阳性。然而，在进行细菌基因组比对后，这些患者的ESBL菌株与对应指数患者的菌株不一致。
> 
> 结论：在地方流行且ICU住院时间较短的情况下，对ESBL-E阳性患者仅实施接触防护而不进行单人病房隔离，并未导致ICU患者间的交叉污染。

### 第二部分 AI 大师评价

本研究采用前瞻性观察设计，评估了在未实施单人病房隔离的情况下，单纯接触防护措施防止ESBL-E交叉传播的有效性。结果显示，该策略在ICU中未导致患者间的交叉感染，为合理化感染防控资源提供了实证依据。研究的优势在于结合了全基因组测序验证交叉传播的分子证据。局限性包括研究为单中心、观察性设计，且ICU滞留时间较短，可能影响外推性。

---

## 4. 床旁应用生理学：将有创血压作为真正的监测工具

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41372508)
**期刊：** Annals of intensive care
**PMID：** 41372508
**DOI：** 10.1186/s13613-025-01608-y

### 第一部分 原文与翻译

**英文原标题：** Applied physiology at the bedside: using invasive blood pressure as a true monitoring tool.

> **英文摘要：**
> Invasive arterial blood pressure (BP) monitoring is a cornerstone of hemodynamic assessment in critically ill patients. This review explores how the individual components of BP-systolic arterial (SAP), diastolic arterial (DAP), mean arterial (MAP), and pulse pressure (PP)-offer valuable insights into cardiovascular physiology and can be leveraged as real-time therapeutic tools in intensive care settings. A strong emphasis is placed on the technical requirements for accurate BP waveform interpretation and the physiological meaning of each BP component. PP is examined as a surrogate for stroke volume and a dynamic marker of fluid responsiveness, particularly in mechanically ventilated patients. DAP is discussed as a reflection of vasomotor tone, with clinical implications for guiding the initiation of vasopressors. The concept of diastolic shock index (DSI) and the newly proposed VNERi ratio (DAP/[Heart rate × norepinephrine dose]) are introduced as potentially superior markers for assessing vascular tone and vasopressor responsiveness, respectively. These indices may facilitate earlier identification of patients requiring escalation of vasopressor therapy, including the initiation of vasopressin in addition to norepinephrine. The review advocates for a physiology-driven, individualized approach to hemodynamic management, using invasive BP not merely as a safety parameter but as an actionable guide for precision resuscitation.

> **中文摘要：**
> 有创动脉血压（BP）监测是重症患者血流动力学评估的基石。本综述探讨了血压的各个组成部分——收缩压（SAP）、舒张压（DAP）、平均动脉压（MAP）和脉压（PP）——如何为心血管生理学提供有价值的洞见，并可在重症监护环境中作为实时治疗工具加以利用。文中重点强调了准确解读血压波形的技术要求以及各血压成分的生理意义。PP被视为搏出量的替代指标和液体反应性的动态标志，尤其在机械通气患者中具有意义。DAP则被讨论为血管运动张力的反映，对指导升压药的启动具有临床意义。文章引入了舒张性休克指数（DSI）以及新提出的VNERi比值（DAP/[心率×去甲肾上腺素剂量]），分别作为评估血管张力和升压药反应性的潜在优越指标。这些指数可能有助于更早识别需要升级升压治疗的患者，包括在去甲肾上腺素基础上启动加压素的时机。综述倡导一种以生理学为驱动、个体化的血流动力学管理方法，将有创血压从单纯的安全参数提升为精准复苏的可操作指导。

### 第二部分 AI 大师评价

该综述旨在重新定义有创血压监测在重症患者中的角色，从传统的安全参数拓展为指导血流动力学干预的动态工具。文献系统阐述了血压各参数的生理意义及技术要求，并引入新指数以优化血管张力与升压反应性的评估。其创新之处在于以实时生理学为核心的个体化管理理念，为精准复苏提供理论支撑。然而，实际应用仍需前瞻性研究验证其指标的临床可行性与预测价值。

---

## 5. cDC1细胞上的促红细胞生成素受体决定免疫耐受性。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41372415)
**期刊：** Nature
**PMID：** 41372415
**DOI：** 10.1038/s41586-025-09824-z

### 第一部分 原文与翻译

**英文原标题：** Erythropoietin receptor on cDC1s dictates immune tolerance.

> **英文摘要：**
> Type 1 conventional dendritic cells (cDC1s) are unique in their efferocytosis and cross-presenting abilities, resulting in antigen-specific T cell immunity or tolerance. However, the mechanisms that underlie cDC1 tolerogenic function remain largely unknown. Here we show that the erythropoietin receptor (EPOR) acts as a critical switch that determines the tolerogenic function of cDC1s and the threshold of antigen-specific T cell responses. In total lymphoid irradiation-induced allograft tolerance, cDC1s upregulate EPOR expression, and conditional knockout of EPOR in cDC1s diminishes antigen-specific induction and expansion of FOXP3 regulatory T (T) cells, resulting in allograft rejection. Mechanistically, EPOR promotes efferocytosis-induced tolerogenic maturation of splenic cDC1s towards late-stage CCR7 cDC1s characterized by increased expression of the integrin β8 gene (Itgb8), and conditional knockout of Itgb8 in cDC1s impairs tolerance induced by total lymphoid irradiation plus anti-thymocyte serum. Migratory cDC1s in peripheral lymph nodes preferentially express EPOR, and their FOXP3 T cell-inducing capacity is enhanced by erythropoietin. Reciprocally, loss of EPOR enables immunogenic maturation of peripheral lymph node migratory and splenic CCR7 cDC1s by upregulating genes involved in MHC class II- and class I-mediated antigen presentation, cross-presentation and costimulation. EPOR deficiency in cDC1s reduces tumour growth by enhancing anti-tumour T cell immunity, particularly increasing the generation of precursor exhausted tumour antigen-specific CD8 T cells in tumour-draining lymph nodes and supporting their maintenance within tumours, while concurrently reducing intratumoural T cells. Targeting EPOR on cDC1s to induce or inhibit T cell immune tolerance could have potential for treating a variety of diseases.

> **中文摘要：**
> 1型常规树突状细胞（cDC1）以其独特的清除凋亡细胞（efferocytosis）及交叉呈递能力而著称，从而诱导抗原特异性T细胞免疫或耐受。然而，支撑cDC1耐受功能的机制尚不清楚。本研究显示，促红细胞生成素受体（EPOR）作为一个关键开关，决定了cDC1的耐受功能以及抗原特异性T细胞反应的阈值。在全淋巴照射诱导的异体移植物耐受中，cDC1上调EPOR的表达，而在cDC1中条件性敲除EPOR会削弱抗原特异性FOXP3调节性T细胞的诱导与扩增，导致移植物排斥。从机制上讲，EPOR促进脾脏cDC1在清除凋亡细胞后向耐受性成熟方向分化，形成晚期CCR7阳性cDC1，其特征是整合素β8基因（Itgb8）表达增加；而在cDC1中条件性敲除Itgb8会削弱全淋巴照射联合抗胸腺细胞血清诱导的免疫耐受。外周淋巴结中的迁移性cDC1优先表达EPOR，其诱导FOXP3 T细胞的能力可被促红细胞生成素增强。相反，EPOR的缺失促使外周淋巴结迁移性及脾脏CCR7阳性cDC1向免疫原性成熟方向转变，伴随与MHC II类及I类介导的抗原呈递、交叉呈递和共刺激相关基因的上调。cDC1中的EPOR缺陷通过增强抗肿瘤T细胞免疫而抑制肿瘤生长，尤其促进肿瘤引流淋巴结中前体耗竭状态的肿瘤抗原特异性CD8 T细胞的产生及其在肿瘤内的维持，同时减少肿瘤内的T细胞。靶向cDC1上的EPOR以诱导或抑制T细胞免疫耐受，可能为多种疾病的治疗提供潜在策略。

### 第二部分 AI 大师评价

本研究揭示了促红细胞生成素受体（EPOR）在cDC1细胞免疫耐受调控中的关键作用，提出其作为“分子开关”在决定T细胞应答命运中的功能。作者通过异体移植模型、条件性敲除实验及基因表达分析，系统阐明EPOR与Itgb8在耐受性成熟及肿瘤免疫中的机制联系。研究创新性地将造血因子信号与树突状细胞介导的免疫平衡相联系，为通过靶向EPOR调节免疫耐受/免疫激活提供了新思路。潜在局限在于模型主要基于小鼠系统，人类应用仍需进一步验证。

---

## 6. 揭示LINE-1在肺腺癌演化中的作用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41372401)
**期刊：** Nature
**PMID：** 41372401
**DOI：** 10.1038/s41586-025-09825-y

### 第一部分 原文与翻译

**英文原标题：** Uncovering the role of LINE-1 in the evolution of lung adenocarcinoma.

> **英文摘要：**
> Understanding lung cancer evolution can identify tools for intercepting its growth. Here, in a landscape analysis of 1,024 lung adenocarcinomas (LUADs) with deep whole-genome sequencing integrated with multiomic data, we identified 542 LUADs with a diverse clonal architecture. In this group, we observed divergent evolutionary trajectories based on tobacco smoking exposure, ancestry and sex. LUAD from smokers showed an abundance of tobacco-related C:G>A:T driver mutations in KRAS and short subclonal diversification. LUAD in people who have never smoked (hereafter, never-smokers) showed early occurrence of copy-number alterations and EGFR mutations associated with SBS5 and SBS40a mutational signatures. Tumours containing EGFR mutations exhibited long latency, particularly in female individuals of European-ancestry. Tumours from Asian never-smokers showed a short clonal evolution. Importantly, we found that the mutational signature ID2 is a marker of a previously unrecognized mechanism for LUAD evolution. Tumours with ID2 showed short latency and high long interspersed nuclear element-1 (LINE-1, hereafter L1) retrotransposon activity linked to L1 promoter demethylation. These tumours exhibited an aggressive phenotype with genomic instability, elevated hypoxia scores, low neoantigen burden, metastasis propensity and poor overall survival. Reactivated L1-retrotransposition-induced mutagenesis probably contributes to the mutational signature ID2, including through the regulation of the transcriptional factor ZNF695, a member of the KZFP family. The complex nature of LUAD evolution creates both challenges and opportunities for screening and treatment plans.

> **中文摘要：**
> 理解肺癌的演化有助于发现阻止其生长的干预工具。在对1,024例肺腺癌（LUAD）进行深度全基因组测序并整合多组学数据的全景分析中，我们鉴定出542例具有多样性克隆结构的LUAD。在该人群中，我们观察到依据烟草暴露、种族和性别而异的不同演化轨迹。吸烟者的LUAD显示出KRAS基因中富集的与烟草相关的C:G>A:T驱动突变，以及较短的亚克隆分化。对于从未吸烟者（以下简称从未吸烟者），LUAD呈现早期发生拷贝数变异及与SBS5和SBS40a突变特征相关的EGFR突变。携带EGFR突变的肿瘤表现出较长的潜伏期，尤其是在具有欧洲血统的女性个体中。亚洲从未吸烟者的肿瘤则展现出较短的克隆演化。重要的是，我们发现突变特征ID2是LUAD演化中一个此前未被认识的机制标志。携带ID2的肿瘤表现出短潜伏期和高水平的长散在核元件-1（LINE-1，以下简称L1）逆转录转座子活性，该活性与L1启动子去甲基化相关。这些肿瘤表现出侵袭性表型，包括基因组不稳定性增加、缺氧评分升高、新抗原负荷低、易转移倾向及总体生存率较差。重新激活的L1逆转录转座诱导突变可能促进了突变特征ID2的形成，包括通过调控KZFP家族成员转录因子ZNF695。LUAD演化的复杂性既带来了筛查和治疗方案上的挑战，也提供了新的机遇。

### 第二部分 AI 大师评价

本研究通过对超过千例肺腺癌的全基因组及多组学整合分析，揭示了吸烟状态、种族和性别在肿瘤演化中的差异性轨迹。作者发现突变特征ID2及其相关的LINE-1逆转座活性是肺腺癌演化的新型分子标志，并与L1启动子去甲基化和ZNF695的调控机制相关。该研究创新性地将转座子活化与肿瘤演化联系起来，为理解非吸烟者肺癌的进化机制提供了重要线索。尽管机制仍需功能验证，但其对精准分层和治疗靶向设计具有潜在价值。

---

## 7. 流感血凝素中的初级奥司他韦耐药突变及其对抗病毒耐药监测的启示

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41372193)
**期刊：** Nature communications
**PMID：** 41372193
**DOI：** 10.1038/s41467-025-66307-5

### 第一部分 原文与翻译

**英文原标题：** A primary oseltamivir-resistant mutation in influenza hemagglutinin and its implications for antiviral resistance surveillance.

> **英文摘要：**
> Oseltamivir, a neuraminidase (NA) inhibitor, is currently the most widely used antiviral drug for influenza worldwide. The emergence of primary oseltamivir-resistant mutations in NA protein of seasonally circulating viruses has been extensively monitored to evaluate drug efficacy. In addition to primary mutations in NA, mutations in the viral hemagglutinin (HA) protein have been observed to arise alongside NA mutations in previous laboratory selection experiments under neuraminidase inhibitor pressure, such HA mutations have not yet been reported in circulating viruses. Here, we present the experimental evidence that an A(H1N1)pdm09 virus can independently acquire oseltamivir-resistance mutations K130N or K130E in the HA receptor binding site (RBS) during serial passages under drug selection. Notably, HA-K130N mutation has been prevalent in currently circulating seasonal viruses worldwide since 2019. More importantly, we demonstrate that the HA-K130N can enhance the oseltamivir resistance conferred by the well-characterized NA-N295S mutation. Our study provides essential evidence that mutations in HA are closely associated with the occurrence of neuraminidase inhibitor resistance, highlighting the urgent need for global monitoring and assessment of oseltamivir-resistant mutations in the HA protein, in addition to NA, during the ongoing H1N1 epidemics.

> **中文摘要：**
> 奥司他韦是一种神经氨酸酶（NA）抑制剂，目前是全球范围内使用最广泛的抗流感药物。为了评估药物疗效，科学界已对季节性流感病毒NA蛋白中初级奥司他韦耐药突变的出现进行了广泛监测。除NA中的初级突变外，在以往的实验室神经氨酸酶抑制剂选择压力实验中，观察到病毒血凝素（HA）蛋白也会伴随NA突变产生突变，但此类HA突变尚未在流行病毒中报道。在本研究中，我们提供了实验证据，说明A(H1N1)pdm09病毒可在药物选择传代过程中，在HA受体结合位点（RBS）上独立获得K130N或K130E奥司他韦耐药突变。值得注意的是，自2019年以来，HA-K130N突变已在全球范围内流行的季节性病毒中普遍存在。更重要的是，我们证明HA-K130N突变可增强由已知NA-N295S突变所赋予的奥司他韦耐药性。本研究提供了关键证据，表明HA突变与神经氨酸酶抑制剂耐药性的发生密切相关，强调在持续的H1N1流行背景下，除NA外，还需对HA蛋白中的奥司他韦耐药突变进行全球监测与评估的紧迫性。

### 第二部分 AI 大师评价

本研究旨在揭示流感病毒血凝素中奥司他韦耐药突变的独立形成机制及其对药物耐药监测的意义。作者通过实验发现A(H1N1)pdm09病毒可在药物压力下自主获得HA-K130N/E突变，并指出其中HA-K130N突变自2019年以来在全球广泛流行。研究进一步证明该HA突变可增强由NA突变造成的奥司他韦耐药性。该发现拓宽了对流感抗药性形成机制的理解，为未来抗病毒监测提供了新靶点，但仍需进一步研究其临床传播影响与分子适应机制。

---

## 8. 患者来源的结肠上皮类器官揭示了儿童溃疡性结肠炎中的脂质相关代谢功能障碍。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41372139)
**期刊：** Nature communications
**PMID：** 41372139
**DOI：** 10.1038/s41467-025-65988-2

### 第一部分 原文与翻译

**英文原标题：** Patient-derived colon epithelial organoids reveal lipid-related metabolic dysfunction in pediatric ulcerative colitis.

> **英文摘要：**
> Ulcerative colitis (UC) is associated with epithelial metabolic derangements which exacerbate gut inflammation. Here, we develop colon organoid (colonoid) lines from pediatric patients with endoscopically active UC, inactive UC, and those without intestinal inflammation to interrogate functional metabolic differences in the colon epithelia. We demonstrate that active UC colonoids exhibit hypermetabolic features and cellular stress, specifically during differentiation. Hypermetabolism in active UC colonoids is driven, in part, by increased proton leak, and excess lipid accumulation. Active UC colonoids exhibit heightened activation of the master lipid regulator PPAR-α and its transcriptional pathways. Pharmacological PPAR-α inhibition limits lipid accumulation, induces a metabolic shift towards glucose utilization, suppresses hypermetabolism, and reduces chemokine secretion and cellular stress markers. Collectively, our findings identify lipid-related metabolic dysfunction as a key pathologic feature of the pediatric UC epithelium and highlight the potential of patient-derived colonoids as a preclinical model for evaluating epithelial-targeted therapies addressing this dysfunction.

> **中文摘要：**
> 溃疡性结肠炎（UC）与上皮代谢紊乱相关，这些紊乱会加重肠道炎症。在本研究中，我们从儿童患者中建立了结肠类器官（colonoid）细胞系，涵盖内镜下活动期UC、非活动期UC以及无肠道炎症者，以探讨结肠上皮的功能代谢差异。我们发现，活动期UC类器官表现出高代谢特征和细胞应激，尤其在分化过程中尤为显著。活动期UC类器官的高代谢部分由质子泄漏增加和脂质过度积累驱动。活动期UC类器官显示出脂质代谢主调控因子PPAR-α及其转录通路的显著激活。药理性抑制PPAR-α可限制脂质积累，诱导代谢转向葡萄糖利用，抑制高代谢状态，并降低趋化因子分泌及细胞应激标志物。综上所述，我们的研究结果表明，脂质相关的代谢功能障碍是儿童UC上皮的关键病理特征，并强调患者来源的类器官在评估针对上皮代谢失调的治疗中的潜在前临床应用价值。

### 第二部分 AI 大师评价

该研究通过建立儿童患者来源的结肠类器官模型，系统揭示活动性溃疡性结肠炎上皮中的脂质相关代谢异常。作者采用多组学及药理干预手段，揭示PPAR-α激活与脂质积累、细胞高代谢及应激反应之间的关系。研究为认识儿童UC的代谢病理机制提供了直接的上皮层证据，并展示了类器官模型在代谢靶向药物筛选中的潜能。其创新性体现在以患者来源的功能模型验证代谢调控通路，但样本规模及临床异质性仍可能限制结论的外推性。

---

## 9. 重症、内科与呼吸医学中的神经结节病：一种实用的诊治策略

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41371265)
**期刊：** Seminars in respiratory and critical care medicine
**PMID：** 41371265
**DOI：** 10.1055/a-2768-3052

### 第一部分 原文与翻译

**英文原标题：** Neurosarcoidosis in Critical Care, Internal and Pulmonary Medicine: A Practical Approach.

> **英文摘要：**
> Neurosarcoidosis is a rare but clinically significant manifestation of sarcoidosis, often presenting with diverse neurologic symptoms that can lead to permanent disability if left untreated. This review aims to provide internists, pulmonologists, non-neurologist clinicians, and critical care specialists with a structured, pragmatic approach to the evaluation, diagnosis, and management of neurosarcoidosis in two distinct patient groups: those with a known diagnosis of systemic sarcoidosis and those with no prior history of sarcoidosis. We emphasize the recognition of key acute clinical syndromes such as seizures, stroke, neuroendocrinopathy, hydrocephalus, meningeal disease, myelopathy, and infectious complications that may be encountered in emergency and critical care scenarios. The management approach, which includes first-line therapies such as glucocorticoids and immunomodulatory treatments such as TNF inhibitors and IL-6 inhibitors, is now accepted in the critical care setting to minimize the development of long-standing neurological complications associated with neurosarcoidosis. Furthermore, there is a critical need for a safe and effective transition to steroid-sparing medications for long-term disease control, while closely monitoring the risk for infections, such as tuberculosis and opportunistic infections, metabolic disturbances, and other complications. Given the significance of neurosarcoidosis as a severe manifestation of systemic sarcoidosis, a multidisciplinary approach is essential to effectively manage both neurological and systemic manifestations.

> **中文摘要：**
> 神经结节病是一种罕见但具有临床重要意义的结节病表现，常表现为多样的神经系统症状；若未及时治疗，可能导致永久性残疾。本综述旨在为内科医师、呼吸科医师、非神经专科临床医师及重症医学专家提供一种结构化且务实的评估、诊断与管理神经结节病的策略，针对两类患者群体：一类为已确诊全身性结节病者，另一类为无既往结节病史者。我们重点强调识别关键的急性临床综合征，包括癫痫发作、卒中、神经内分泌病、脑积水、脑膜疾病、脊髓病及在急诊与重症医学环境中可能遇到的感染性并发症。治疗方法包括以糖皮质激素为一线治疗以及肿瘤坏死因子（TNF）抑制剂、白介素-6（IL-6）抑制剂等免疫调节治疗，目前在重症监护环境中逐渐被接受，以减少神经结节病相关的长期神经系统并发症。此外，还迫切需要安全有效地过渡至可减少糖皮质激素使用的维持治疗药物，以实现疾病的长期控制，同时需密切监测感染风险，如结核、机会性感染、代谢紊乱及其他并发症。鉴于神经结节病作为系统性结节病重症表现的重要性，采用多学科协作方式以有效管理神经及全身表现至关重要。

### 第二部分 AI 大师评价

本文综述系统总结了神经结节病在重症、内科与呼吸医学中的诊疗策略，尤其聚焦急性神经综合征的识别及免疫调节治疗的合理应用。作者提出了清晰的分层管理路径，并强调了糖皮质激素向免疫调节药物的安全过渡，这对于长期控制疾病具有实践价值。文章的创新点在于将重症管理视角融入神经结节病治疗框架，体现了跨学科整合思维。其局限在于主要依据现有文献观点，缺乏前瞻性临床数据验证。

---

## 10. 腹膜透析结局与实践模式研究中的性别特异性结局

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41370095)
**期刊：** Clinical journal of the American Society of Nephrology : CJASN
**PMID：** 41370095
**DOI：** 10.2215/CJN.0000000937

### 第一部分 原文与翻译

**英文原标题：** Sex-Specific Outcomes in The Peritoneal Dialysis Outcomes and Practice Patterns Study.

> **英文摘要：**
> BACKGROUND: Sex differences may influence peritoneal dialysis (PD) outcomes for individuals with kidney failure and remain poorly understood. Understanding these differences is important in optimizing dialysis care and addressing disparities in treatment outcomes We sought to explore association of sex with PD outcomes.
> 
> METHODS: Data from the international PD Outcomes and Practice Patterns Study (PDOPPS) across eight countries was used to examine sex differences in outcomes, including mortality, transfer to hemodialysis HD, the composite of both, peritonitis risks and kidney transplantation. Cause-specific Cox regression models were used to assess the association between sex and each clinical outcome, adjusting for region, comorbidities, demographic and treatment characteristics.
> 
> RESULTS: Of 26,292 included individuals on PD, 43% were female, ranging from 34% in Japan to 51% in Thailand. Females (compared to males) had lower mortality (rate per 100 patient years [PY100]=10.9 vs.11.3; adjusted hazard ratio {aHR} of mortality 0.92 [95% confidence intervals {CI} 0.86-0.99]), transfer to hemodialysis (PY100=16.3 vs.17.9; aHR=0.87 [95%CI 0.83-0.92]), the composite of both (PY100=27.2 vs.29.0; aHR=0.89 [95% CI 0.85-0.93]) and time to first observed peritonitis (PY100=17.5 vs.18.7; aHR=0.90 [95% CI 0.84-0.95]), while transplant hazards were similar (PY100=4.0 vs.4.0; aHR=0.97 [95% CI 0.87-1.08]). In subgroup and additional analyses, sex differences in outcomes were particularly apparent in South Korea (SK), with a median time on PD of 6.4 years for females and 4.9 years for males, with SK females having lower hemodialysis transfer and transplant rates. Across all countries, diabetes substantially attenuated the lower risks of death and hemodialysis transfer in females. Females had significantly lower risks of gram-positive peritonitis (aHR=0.73 [95% CI 0.65-0.82]).
> 
> CONCLUSIONS: Compared to males, females receiving PD have lower likelihoods of mortality, hemodialysis transfer and peritonitis. Better understanding of these findings will help inform sex-specific strategies for managing PD while enhancing personalized care approaches in this patient population.

> **中文摘要：**
> 背景：性别差异可能会影响肾衰竭患者的腹膜透析（PD）结局，但目前仍知之甚少。理解这些差异对于优化透析护理和减少治疗结局的不平等至关重要。本研究旨在探讨性别与PD结局的关联。
> 
> 方法：研究利用涵盖八个国家的国际腹膜透析结局与实践模式研究（PDOPPS）数据，分析了包括死亡率、转为血液透析（HD）、两者的复合结局、腹膜炎风险以及肾移植在内的多种结局的性别差异。采用原因特异性Cox回归模型评估性别与各临床结局的关系，并调整了地区、合并症、人口学与治疗特征等因素。
> 
> 结果：共纳入26,292例PD患者，其中女性占43%，比例从日本的34%至泰国的51%不等。女性患者（与男性相比）死亡率较低（每百人年[PY100]为10.9 vs. 11.3；死亡调整后风险比[aHR]为0.92［95%置信区间[CI] 0.86-0.99］），转为血液透析的风险较低（PY100=16.3 vs.17.9；aHR=0.87［95%CI 0.83-0.92］），两者复合结局的风险较低（PY100=27.2 vs.29.0；aHR=0.89［95%CI 0.85-0.93］），首次腹膜炎发生的风险较低（PY100=17.5 vs.18.7；aHR=0.90［95%CI 0.84-0.95］），而移植风险相似（PY100=4.0 vs.4.0；aHR=0.97［95%CI 0.87-1.08］）。亚组及补充分析显示，性别差异在韩国尤为明显，女性PD中位使用时长6.4年，男性为4.9年，韩国女性患者转为血液透析和移植率更低。在各国范围内，糖尿病显著削弱了女性在死亡和血透转移风险方面的优势。女性患者的革兰阳性菌腹膜炎风险显著较低（aHR=0.73［95%CI 0.65-0.82］）。
> 
> 结论：与男性相比，接受PD的女性患者在死亡率、转为血液透析及腹膜炎发生方面的风险均较低。深入理解这些发现将有助于制定性别特异的PD管理策略，并促进该患者群体的个体化治疗。

### 第二部分 AI 大师评价

本研究基于国际PDOPPS大型多国数据，系统评估了腹膜透析患者结局的性别差异。研究采用多因素Cox回归模型，严格控制混杂因素，发现女性较男性具有更低的死亡率、血透转移和腹膜炎风险，而移植率差异不显著。该研究在全球范围提供了高质量的实证证据，突出了性别在PD管理中的重要性。其创新性在于广泛的国际数据及多层次分析，但局限性可能在于观察性研究的因果推断能力有限。

---

## 11. 高剂量流感疫苗对老年人住院预防效果的研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40888720)
**期刊：** The New England journal of medicine
**PMID：** 40888720
**DOI：** 10.1056/NEJMoa2509907

### 第一部分 原文与翻译

**英文原标题：** High-Dose Influenza Vaccine Effectiveness against Hospitalization in Older Adults.

> **英文摘要：**
> BACKGROUND: High-dose inactivated influenza vaccine has been shown to provide protection against influenza that is superior to that with the standard dose. However, data from individually randomized trials on the effectiveness of the high-dose vaccine against severe outcomes are limited.
> 
> METHODS: In this pragmatic, open-label, randomized, controlled trial conducted in Denmark during the 2022-2023, 2023-2024, and 2024-2025 influenza seasons, we assigned older adults (≥65 years of age) to receive the high dose of the inactivated influenza vaccine or the standard dose. Data collection relied on nationwide administrative health registries. The primary end point was hospitalization for influenza or pneumonia that occurred from 14 days after vaccination through May 31 of the following year.
> 
> RESULTS: Of the 332,438 participants who underwent randomization, 166,218 were assigned to receive the high-dose vaccine and 166,220 to receive the standard-dose vaccine. The mean (±SD) age of the participants was 73.7±5.8 years, and 161,538 participants (48.6%) were women. A primary end-point event occurred in 1138 participants (0.68%) in the high-dose group and in 1210 (0.73%) in the standard-dose group (relative vaccine effectiveness, 5.9%; 95.2% confidence interval [CI], -2.1 to 13.4; P = 0.14). Hospitalization for influenza occurred in 0.06% of the participants in the high-dose group and in 0.11% of those in the standard-dose group (relative vaccine effectiveness, 43.6%; 95.2% CI, 27.5 to 56.3); hospitalization for pneumonia occurred in 0.63% and 0.63%, respectively (relative effectiveness, 0.5%; 95.2% CI, -8.6 to 8.8); hospitalization for cardiorespiratory disease in 2.25% and 2.38% (relative effectiveness, 5.7%; 95.2% CI, 1.4 to 9.9); hospitalization for any cause in 9.38% and 9.58% (relative effectiveness, 2.1%; 95.2% CI, -0.1 to 4.3), and death from any cause in 0.67% and 0.66% (relative effectiveness, -2.5%; 95.2% CI, -11.6 to 5.9). The incidence of serious adverse events was similar in the two groups.
> 
> CONCLUSIONS: In this trial, a high-dose inactivated influenza vaccine did not result in a significantly lower incidence of hospitalization for influenza or pneumonia than a standard dose among older adults. (Funded by Sanofi; DANFLU-2 ClinicalTrials.gov number, NCT05517174; EU Clinical Trials Register number, 2022-500657-17-00.).

> **中文摘要：**
> 背景：研究表明，高剂量灭活流感疫苗在预防流感方面较标准剂量具有更优的保护效果。然而，关于高剂量疫苗对重症结局保护效果的个体随机对照试验数据仍然有限。
> 
> 方法：在本项务实性、开放标签、随机对照试验中，研究于丹麦在2022–2023、2023–2024及2024–2025三个流感季节实施。研究对象为年龄在65岁及以上的老年人，随机分配接受高剂量或标准剂量灭活流感疫苗。数据收集依托全国行政卫生登记数据库。主要终点为接种疫苗后14天至次年5月31日期间发生的流感或肺炎住院事件。
> 
> 结果：共332,438名参与者随机分组，其中166,218人接受高剂量疫苗，166,220人接受标准剂量疫苗。受试者平均年龄为73.7±5.8岁，女性161,538人（48.6%）。主要终点事件分别发生于高剂量组1138例（0.68%）与标准剂量组1210例（0.73%）（相对疫苗有效性5.9%；95.2%置信区间[-2.1, 13.4]；P=0.14）。流感住院率分别为0.06%与0.11%（相对有效性43.6%；95.2%置信区间[27.5, 56.3]）；肺炎住院率分别为0.63%与0.63%（相对有效性0.5%；95.2%置信区间[-8.6, 8.8]）；心肺疾病住院率为2.25%与2.38%（相对有效性5.7%；95.2%置信区间[1.4, 9.9]）；任何原因住院率为9.38%与9.58%（相对有效性2.1%；95.2%置信区间[-0.1, 4.3]）；任何原因死亡率为0.67%与0.66%（相对有效性-2.5%；95.2%置信区间[-11.6, 5.9]）。两组严重不良事件发生率相似。
> 
> 结论：在本试验中，高剂量灭活流感疫苗并未显著降低老年人因流感或肺炎而住院的发生率，相较标准剂量无统计学显著差异。（由赛诺菲资助；DANFLU-2临床试验注册号：NCT05517174；欧盟临床试验注册号：2022-500657-17-00。）

### 第二部分 AI 大师评价

本研究为丹麦多季节、全国登记数据支持的随机对照试验，评估高剂量流感疫苗在老年人中预防住院的效果。结果显示，高剂量组在总体流感或肺炎住院方面并未优于标准剂量，但在流感单独住院方面呈现一定优势。试验规模庞大、设计务实，增强了真实世界适用性。然而，结果提示高剂量疫苗对严重结局的额外效益有限，未来研究需进一步识别受益人群与成本效益。

---

## 12. 高剂量流感疫苗在减少住院方面的效果研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40888694)
**期刊：** The New England journal of medicine
**PMID：** 40888694
**DOI：** 10.1056/NEJMoa2509834

### 第一部分 原文与翻译

**英文原标题：** High-Dose Influenza Vaccine to Reduce Hospitalizations.

> **英文摘要：**
> BACKGROUND: Superior protection against laboratory-confirmed influenza has been proved for high-dose inactivated influenza vaccine, as compared with the standard dose, among adults 65 years of age or older. However, data on the relative effectiveness of the high-dose vaccine against severe clinical outcomes, including hospitalizations, are limited.
> 
> METHODS: We conducted a pragmatic, registry-based, open-label, randomized, active-controlled trial to evaluate the relative effectiveness of high-dose inactivated influenza vaccine, as compared with the standard dose, against severe clinical outcomes among community-dwelling adults 65 to 79 years of age. The trial was performed during two influenza seasons (2023-2024 and 2024-2025) with regional health registry data in Galicia, Spain. In each influenza season, the participants were randomly assigned in a 1:1 ratio to receive high-dose inactivated influenza vaccine or the standard dose. The primary end point was a composite of hospitalization for influenza or pneumonia from 14 days after vaccination to May 31 of the following year.
> 
> RESULTS: A total of 103,169 unique participants underwent randomization; 31,307 participants were enrolled in both seasons and were counted for each. During the 2023-2024 and 2024-2025 seasons, 59,490 and 74,986 participants, respectively, underwent randomization. Among the participants, the mean (±SD) age was 72.3±4.3 years, and 53.6% were men. A primary end-point event occurred in 174 of 67,093 participants (absolute risk, 0.26%) in the high-dose group and in 227 of 66,789 (absolute risk, 0.34%) in the standard-dose group (relative vaccine effectiveness, 23.7%; 95% confidence interval [CI], 6.6 to 37.7). Hospitalization for influenza occurred in 63 of 67,093 participants (absolute risk, 0.09%) in the high-dose group and in 92 of 66,789 (absolute risk, 0.14%) in the standard-dose group (relative vaccine effectiveness, 31.8%; 95% CI, 5.0 to 51.3). The incidence of serious adverse events appeared to be similar in the two trial groups.
> 
> CONCLUSIONS: Among community-dwelling adults 65 to 79 years of age, there appeared to be fewer hospitalizations for influenza or pneumonia with high-dose inactivated influenza vaccine than with the standard dose. (Funded by Sanofi; GALFLU ClinicalTrials.gov number NCT06141655; EudraCT number, 2023-506977-36-00.).

> **中文摘要：**
> 背景：研究表明，与标准剂量相比，高剂量灭活流感疫苗可在65岁及以上成年人中提供更优的对实验室确诊流感的保护。然而，关于高剂量疫苗针对包括住院在内的严重临床结局的相对有效性数据仍然有限。
> 
> 方法：我们开展了一项务实的、基于登记的、开放标签、随机、活性对照试验，以评估在65至79岁社区居住成年人中，高剂量灭活流感疫苗相对于标准剂量疫苗在预防严重临床结局方面的相对有效性。该试验在西班牙加利西亚地区，利用地区卫生注册数据，于两个流感季节（2023–2024和2024–2025）实施。在每个流感季节，参与者按1:1比例随机分配，接受高剂量灭活流感疫苗或标准剂量。主要终点为自接种后14天起至次年5月31日期间发生的流感或肺炎住院的复合事件。
> 
> 结果：共103,169名独立参与者接受了随机分配；其中31,307名在两个季节均参与并分别计入。于2023–2024及2024–2025流感季，共有59,490名和74,986名参与者被随机分配。参与者平均年龄为72.3±4.3岁，男性占53.6%。主要终点事件在高剂量组的67,093名参与者中发生174例（绝对风险0.26%），在标准剂量组的66,789名参与者中发生227例（绝对风险0.34%）；相对疫苗有效性为23.7%（95%置信区间：6.6至37.7）。流感相关住院在高剂量组中发生63例（绝对风险0.09%），在标准剂量组中发生92例（绝对风险0.14%）；相对疫苗有效性为31.8%（95%置信区间：5.0至51.3）。两组严重不良事件发生率相似。
> 
> 结论：在65至79岁社区居住的成年人中，高剂量灭活流感疫苗较标准剂量疫苗可减少流感或肺炎住院的发生。（由赛诺菲资助；GALFLU试验，ClinicalTrials.gov编号NCT06141655；EudraCT编号2023-506977-36-00。）

### 第二部分 AI 大师评价

本研究是一项基于西班牙地区健康登记系统的大规模随机对照试验，旨在比较高剂量与标准剂量灭活流感疫苗在预防严重结局方面的相对有效性。结果显示，高剂量疫苗能显著降低流感及肺炎相关住院风险，且安全性相当。研究创新在于采用真实世界登记数据与双季节设计，增强了结果的外推性。其局限性包括开放标签设计可能带来观察者偏倚，以及研究区域性限制影响普遍性。

---

速递结束，祝您工作愉快！